JaeDuk Choi

Statistics

Publications

Citations

120

H-Index

Active since

2020

Affiliations

Hanmi Pharmaceutical (South Korea)(Current)

Sanofi (Germany)

JaeDuk Choi is an author at Hanmi Pharmaceutical (South Korea) specializing in medicine, glucagon-like peptide-1 receptor agonists, and liver disease.

Publications per year

2020–2023

Publications

A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis – Study design and rationale of HM-TRIA-201 study

Manal F. Abdelmalek, Ayako Suzuki, Willian Sanchez et al. · Contemporary Clinical Trials · 2023 · 44 citations

Medicine, Internal Medicine, Hepatology +9

Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial

Juan P. Frías, JaeDuk Choi, Julio Rosenstock et al. · Diabetes Care · 2022 · 37 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

HM15211, a novel GLP-1/GIP/Glucagon triple-receptor co-agonist significantly reduces liver fat and body weight in obese subjects with non-alcoholic fatty liver disease: A Phase 1b/2a, multi-center, randomized, placebo-controlled trial

Manal F. Abdelmalek, JaeDuk Choi, Young-Min Kim et al. · Journal of Hepatology · 2020 · 28 citations

Medicine, Endocrinology, Pharmacology +17

Efficacy and safety of <scp>once‐weekly</scp> efpeglenatide in people with suboptimally controlled type 2 diabetes: The <scp>AMPLITUDE‐D</scp> , <scp>AMPLITUDE‐L</scp> and <scp>AMPLITUDE‐S</scp> randomized controlled trials

Vanita R. Aroda, Juan P. Frías, Linong Ji et al. · Diabetes Obesity and Metabolism · 2023 · 11 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

1–4 of 4